Image_1_Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.jpg (1.62 MB)
Download file

Image_1_Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.jpg

Download (1.62 MB)
figure
posted on 21.06.2019, 10:46 authored by Ismael Artur da Costa-Rocha, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhães, Jordana Grazziela Coelho-dos-Reis, Jordana Rodrigues Barbosa Fradico, Thalles Souza-Lopes, Laise Rodrigues Reis, Larissa Chaves Freire, Christiane Costa-Pereira, Juliana Vaz de Melo Mambrini, Maria de Lourdes de Sousa Maia, Sheila Maria Barbosa de Lima, Tatiana Guimarães de Noronha, Janaina Reis Xavier, Luiz Antonio Bastos Camacho, Elizabeth Maciel de Albuquerque, Roberto Henrique Guedes Farias, Thalita da Matta de Castro, Akira Homma, Alessandro Pecego Martins Romano, Carla Magda Domingues, Reinaldo de Menezes Martins, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho

The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). For this purpose, this follow-up study was carried out in a subset of volunteers (n = 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations (“EMCD4,EMCD8” and “TNFCD8,IFNCD8”) observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults.

History